HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 03 2019
Historique:
received: 06 11 2017
accepted: 04 02 2019
entrez: 6 3 2019
pubmed: 6 3 2019
medline: 21 10 2020
Statut: epublish

Résumé

The HER2 oncogene and its truncated form p95HER2 play central roles in breast cancer. Here, we show that although HER2 and p95HER2 generally elicit qualitatively similar changes in miRNA profile in MCF-7 breast cancer cells, a subset of changes are distinct and p95HER2 shifts the miRNA profile towards the basal breast cancer subtype. High-throughput miRNA profiling was carried out 15, 36 and 60 h after HER2 or p95HER2 expression and central hits validated by RT-qPCR. miRNAs strongly regulated by p95HER2 yet not by HER2, included miR-221, miR-222, miR-503, miR-29a, miR-149, miR-196 and miR-361. Estrogen receptor-α (ESR1) expression was essentially ablated by p95HER2 expression, in a manner recapitulated by miR-221/-222 mimics. c-Myb family transcription factors MYB and MYBL1, but not MYBL2, were downregulated by p95HER2 and by miR-503 or miR-221/-222 mimics. MYBL1 3'UTR inhibition by miR-221/222 was lost by deletion of a single putative miR-221/222 binding sites. p95HER2 expression, or knockdown of either MYB protein, elicited upregulation of tissue inhibitor of matrix metalloprotease-2 (TIMP2). miR-221/222 and -503 mimics increased, and TIMP2 knockdown decreased, cell migration and invasion. A similar pathway was operational in T47D- and SKBr-3 cells. This work reveals important differences between HER2- and p95HER2- mediated miRNA changes in breast cancer cells, provides novel mechanistic insight into regulation of MYB family transcription factors by p95HER2, and points to a role for a miR-221/222- MYB family-TIMP2 axis in regulation of motility in breast cancer cells.

Identifiants

pubmed: 30833639
doi: 10.1038/s41598-019-39733-x
pii: 10.1038/s41598-019-39733-x
pmc: PMC6399295
doi:

Substances chimiques

MIRN221 microRNA, human 0
MIRN222 microRNA, human 0
MIRN503 microRNA, human 0
MYB protein, human 0
MicroRNAs 0
Protein Isoforms 0
Proto-Oncogene Proteins c-myb 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3352

Références

Genes Dev. 2014 Apr 1;28(7):765-82
pubmed: 24636986
Cancer Res. 2000 Aug 15;60(16):4519-25
pubmed: 10969801
Cancer Res. 2010 Nov 1;70(21):8537-46
pubmed: 20978202
FASEB J. 2014 Jan;28(1):350-63
pubmed: 24088818
Oncotarget. 2014 Mar 15;5(5):1174-84
pubmed: 24632568
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Cancer Discov. 2016 Feb;6(2):176-87
pubmed: 26631070
Front Biosci (Landmark Ed). 2011 Jan 01;16:1109-31
pubmed: 21196221
EMBO J. 2001 Sep 3;20(17):4782-93
pubmed: 11532942
J Biol Chem. 2008 Oct 31;283(44):29897-903
pubmed: 18708351
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Clin Cancer Res. 2015 Jan 15;21(2):373-85
pubmed: 25370469
Cell Mol Life Sci. 2003 Nov;60(11):2389-401
pubmed: 14625684
Blood. 1996 Mar 1;87(5):1900-11
pubmed: 8634438
Br J Cancer. 2013 Nov 12;109(10):2714-23
pubmed: 24129242
Oncogene. 1999 May 13;18(19):3017-33
pubmed: 10378697
Cancer Res. 1998 Nov 15;58(22):5123-9
pubmed: 9823322
J Natl Cancer Inst. 2007 Apr 18;99(8):628-38
pubmed: 17440164
Proc Natl Acad Sci U S A. 2013 May 14;110(20):8188-93
pubmed: 23633565
Oncogene. 2009 Feb 5;28(5):742-51
pubmed: 19043454
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):264-9
pubmed: 20018759
Oncology. 2016;90(4):221-31
pubmed: 26999740
Blood Cells Mol Dis. 2003 Sep-Oct;31(2):192-200
pubmed: 12972026
Biochem J. 2016 Nov 1;473(21):4027-4044
pubmed: 27609814
J Natl Cancer Inst. 2010 May 19;102(10):706-21
pubmed: 20388878
Cancer Lett. 2001 Sep 28;171(1):87-101
pubmed: 11485831
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Rev Cancer. 2008 Jul;8(7):523-34
pubmed: 18574464
J Biol Chem. 2008 Nov 7;283(45):31079-86
pubmed: 18790736
Cancer Res. 2013 Jan 1;73(1):450-8
pubmed: 23288917
Tumour Biol. 2015 May;36(5):3763-73
pubmed: 25731730
Blood Cells Mol Dis. 2001 Mar-Apr;27(2):459-63
pubmed: 11259168
J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):65-77
pubmed: 22350980
Breast Cancer Res. 2013 Feb 07;15(1):R11
pubmed: 23391338
Oncogene. 1997 Aug 28;15(9):1011-9
pubmed: 9285555
Oncotarget. 2015;6(12):9794-806
pubmed: 25909166
Int J Cancer. 2001 Oct 15;94(2):185-91
pubmed: 11668496
Mol Cell Biol. 2009 Jun;29(12):3319-31
pubmed: 19364815
Cancer Res. 2011 Aug 15;71(16):5370-3
pubmed: 21828240
Oncogene. 2003 Jan 16;22(2):308-13
pubmed: 12527900
Oncogene. 1990 Jan;5(1):131-5
pubmed: 2181374
Tumour Biol. 2016 Jul;37(7):9181-7
pubmed: 26768615
Genome Res. 2014 May;24(5):869-84
pubmed: 24515121
Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13762-7
pubmed: 17690249
Anticancer Res. 2015 Mar;35(3):1447-51
pubmed: 25750296
Mol Cancer Res. 2015 Jan;13(1):63-77
pubmed: 25143433
Oncologist. 2010;15(7):673-82
pubmed: 20576643
Cancer Res. 2011 Mar 1;71(5):1515-9
pubmed: 21343397
Breast Cancer Res. 2009;11(3):R27
pubmed: 19432961
N Engl J Med. 2013 May 2;368(18):1685-94
pubmed: 23534542
Mol Cancer Res. 2003 Feb;1(4):300-11
pubmed: 12612058
Cancer Res. 2000 Oct 1;60(19):5323-8
pubmed: 11034064

Auteurs

Andrej Gorbatenko (A)

Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, 10029, USA.
Section for Cell Biology and Physiology, Department of Biology, Faculty of Science, University of Copenhagen, Universitetsparken 13, DK-2100, Copenhagen, Denmark.

Rolf Søkilde (R)

BioCare, Strategic Cancer Research Program, Lund, Sweden.
Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of Medicine, Lund University, Lund, Sweden.

Ester E Sorensen (EE)

Section for Cell Biology and Physiology, Department of Biology, Faculty of Science, University of Copenhagen, Universitetsparken 13, DK-2100, Copenhagen, Denmark.

Inga Newie (I)

BioCare, Strategic Cancer Research Program, Lund, Sweden.
Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of Medicine, Lund University, Lund, Sweden.

Helena Persson (H)

BioCare, Strategic Cancer Research Program, Lund, Sweden.
Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of Medicine, Lund University, Lund, Sweden.

Beatriz Morancho (B)

Preclinical Research Program, Vall d'Hebron Institute of Oncology and CIBERONC, 08035, Barcelona, Spain.

Joaquin Arribas (J)

Preclinical Research Program, Vall d'Hebron Institute of Oncology and CIBERONC, 08035, Barcelona, Spain.
Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Campus de la UAB, JA, Bellaterra, Spain.
Institució Catalana de Recerca i Estudis Avançats, JA, Barcelona, Spain.

Thomas Litman (T)

Department of International Health, Immunology and Microbiology, University of Copenhagen, Blegdamsvej 3B, DK-2200, Copenhagen, Denmark.

Carlos Rovira (C)

BioCare, Strategic Cancer Research Program, Lund, Sweden.
Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of Medicine, Lund University, Lund, Sweden.

Stine Falsig Pedersen (SF)

Section for Cell Biology and Physiology, Department of Biology, Faculty of Science, University of Copenhagen, Universitetsparken 13, DK-2100, Copenhagen, Denmark. sfpedersen@bio.ku.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH